Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$75.13 USD

75.13
451,876

+0.13 (0.17%)

Updated May 31, 2024 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific Up on Possible Takeover Bid by Stryker

Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.

    Company News For Jun 12, 2018

    Companies In The News are: EVHC,BSX,SYK,SRE,ADNT

      Boston Scientific (BSX) Looks Good: Stock Adds 7.4% in Session

      Boston Scientific (BSX) shares rose more than 7% in the last trading session, amid huge volumes.

        Stryker Likely to Acquire Boston Scientific, Shares Down

        Per Reuters and The Wall Street Journal, Stryker (SYK) is likely to acquire Boston Scientific. However, there are no confirmatory statements from the company representatives.

          Boston Scientific Grows on New Products Amid Recall Issues

          Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

            Nabaparna Bhattacharya headshot

            US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch

            Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market

              Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?

              Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Here's Why You Should Buy Boston Scientific (BSX) Stock Now

                Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.

                  Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View

                  Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.

                    Boston Scientific (BSX) Beats on Q1 Earnings and Revenues

                    Boston Scientific (BSX) has posted impressive results by delivering revenue growth across all segments in Q1.

                      Medical Product Stock Earnings Roster for Apr 25: LH & More

                      Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

                        Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?

                        Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.

                          WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes

                          The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.

                            Boston Scientific to Acquire Securus Medical, Boost EP Unit

                            Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                              Boston Scientific to Buy NxThera, Strengthens Urology Arm

                              Even after the NxThera purchase deal culminates, it is not likely to add stimulus to Boston Scientific's (BSX) adjusted earnings per share through 2020 and prove to be accretive only later.

                                Sweta Jaiswal headshot

                                Can Boston Scientific's Pain be a Boon for Edwards & Others?

                                Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.

                                  Boston Scientific's Positive Trial Results to Boost EP Unit

                                  Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                                    Urmimala Biswas headshot

                                    Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

                                    According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.

                                      3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax

                                      Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.

                                        Company News For Mar 6, 2018

                                        Companies in the news are: YY,XL,BSX,WMT

                                          Boston Scientific Acquires EMcision, Boosts Endoscopy Unit

                                          Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.

                                            Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                            Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                                Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

                                                Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.

                                                  Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

                                                  Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.